Virtual Library
Start Your Search
X. Hu
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-024 - The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis (ID 3956)
14:30 - 14:30 | Author(s): X. Hu
- Abstract
Background:
This study was conducted to extract a specific conclusion about the clinical efficacy of paclitaxel liposome in non-small cell lung cancer (NSCLC).
Methods:
Pubmed, Embase and Chinese National Knowledge Infrastructure (CNKI) databases were searched for potential relevant articles. Relative risks (RRs) with 95% confidence intervals (CIs) represented the influences of paclitaxel liposome on the objective response rate (ORR), disease control rate (DCR) and adverse events. I2＞50% and P＜0.05 indicate significant heterogeneity. If there existed heterogeneity, then the random-effects model was used. Otherwise, the fixed-effects model was adopted. Sensitivity analysis was performed to test the robustness of overall results. Begg’s funnel plot and Egger’s linear regression test were used to evaluate the potential publication bias.
Results:
The results indicated that paclitaxel liposome could improve the ORR of NSCLC patients (RR=1.22, 95%CI=1.03-1.44). Moreover, we observed that paclitaxel liposome was related with enhanced DCR as well (RR=1.08, 95%CI=1.01-1.16). The influences of paclitaxel liposome on the occurrences of adverse events were analyzed. The outcome suggested that paclitaxel liposome could inhibit the occurrences of muscle pain during the therapy (RR=0.34, 95%CI=0.26-0.45). Besides, onset of rash could also be inhibit by paclitaxel liposome (RR=0.17, 95%CI=0.08-0.35). Sensitivity analysis indicated that the overall results were robust. The funnel plot seemed to be symmetry (P=0.669).
Conclusion:
Paclitaxel liposome is an effective anti-cancer drugs for NSCLC patients.
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-085 - The Combination Therapy of S-1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease (ID 4078)
14:30 - 14:30 | Author(s): X. Hu
- Abstract
Background:
There is no optimal therapy established for those who have progressed with the Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). And some preclinical study indicated that the addition of S-1 to EGFR-TKIs might overcome EGFR-TKI resistance. This study was conducted to investigate the efficacy and safety of the combination therapy of S-1 and EGFR-TKIs for patients failed the previous EGFR-TKI treatments.
Methods:
All patients who received the combination therapy of S-1 and EGFR-TKIs beyond progressive disease with EGFR-TKI monotherapy in the Cancer Hospital, the Chinese Academy of Medical Sciences between 2013 and 2016 with complete records were enrolled in this study. The primary endpoint was progression-free survival (PFS), while the disese control rate and safty were secondary endpoints. Multivariate analysis for survival was conducted including age, gender, initiation of EGFR-TKI, the choice of EGFR-TKI, the best efficacy while using EGFR monotherapy and the choice of S-1 and EGFR-TKI.
Results:
A total of 43 non-small-lung cancer (NSCLC) patients who met the inclusion criteria were enrolled in this study. The median PFS for all patients was 5.47 months (95% confidence interval [CI] 3.444-7.489). The disease control rate is 67.4%(29/43). There was no grade 4 toxicity and no grade 3 hematologic toxicity in this study. One patient has grade 3 elevated total serum bilirubin. Cox analysis showed that the combination treatment of S-1 and erlotinib was associated with decreased PFS comparing the gefitinib (hazards ratio[HR] 8.401, 95% CI 2.781-25.379, p<0.001). Besides, male (HR 0.389, 95%CI 0.162-0.934, p=0.035) and patients with SD (HR 0.303, 95%CI 0.124-0.471, p=0.009) or PD (HR 0.031, 95%CI 0.002-0.450, p=0.011) in the monotherapy of EGFR-TKIs were associated with increased PFS.
Conclusion:
The combination treatment of S-1 and EGFR-TKIs is effective and well-tolerated treatment for those failed prior EGFR-TKI. This strategy is promising to overcome EGFR-TKI resistance in NSCLC. A prospective study will be needed to confirm our studys.
